Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation ... (more)
http://www.bioresearchonline.com/doc.mvc/fate-therapeutics-initiates-prohema-treatment-malignancies-0001?atc~c=771+s=773+r=001+l=a
http://www.bioresearchonline.com/doc.mvc/fate-therapeutics-initiates-prohema-treatment-malignancies-0001?atc~c=771+s=773+r=001+l=a
No comments:
Post a Comment